Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.

Hyde, C; Wake, B; Bryan, S; Barton, P; Fry-Smith, A; Davenport, C; Song, F

Hyde, C; Wake, B; Bryan, S; Barton, P; Fry-Smith, A; Davenport, C; Song, F.

Affiliation

Hyde C; Department of Public Health and Epidemiology, University of Birmingham, UK.

Health Technol Assess ; 6(2): 1-89, 2002.

Article in En | MEDLINE | ID: mdl-12022937

Subject(s)

Antineoplastic Agents/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Vidarabine/therapeutic use; Antineoplastic Agents/adverse effects; Antineoplastic Agents/economics; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/economics; Bone Marrow/drug effects; Bone Marrow/pathology; Cost of Illness; Cost-Benefit Analysis; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/economics; Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology; Leukemia, Lymphocytic, Chronic, B-Cell/mortality; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical; Treatment Outcome; United Kingdom/epidemiology; Vidarabine/adverse effects; Vidarabine/analogs & derivatives; Vidarabine/economics

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Vidarabine / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Antineoplastic Agents Type of study: Clinical_trials / Health_technology_assessment Limits: Humans Country/Region as subject: Europa Language: En Journal: Health Technol Assess Journal subject: PESQUISA EM SERVICOS DE SAUDE / TECNOLOGIA MEDICA Year: 2002 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links